L3VLUP
ProSign in

PRME · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PRMEARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PRME
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterPRMEARGX
Q3 2020none listed holders, n.a.8 holders, $3.6bn
Q4 2020none listed holders, n.a.7 holders, $4.1bn
Q1 2021none listed holders, n.a.8 holders, $4.1bn
Q2 2021none listed holders, n.a.9 holders, $4.6bn
Q3 2021none listed holders, n.a.8 holders, $4.5bn
Q4 2021none listed holders, n.a.9 holders, $5.3bn
Q1 2022none listed holders, n.a.8 holders, $5.3bn
Q2 2022none listed holders, n.a.13 holders, $6.5bn
Q3 2022none listed holders, n.a.14 holders, $5.3bn
Q4 20222 holders, $40m13 holders, $5.5bn
Q1 20232 holders, $30m13 holders, $5.9bn
Q2 20232 holders, $42m18 holders, $6.6bn
Q3 20232 holders, $29m21 holders, $8.7bn
Q4 20232 holders, $29m17 holders, $6.3bn
Q1 20243 holders, $51m13 holders, $6.8bn
Q2 20243 holders, $38m14 holders, $7.9bn
Q3 20243 holders, $27m13 holders, $10.7bn
Q4 20243 holders, $19m14 holders, $12.3bn
Q1 20253 holders, $8.6m17 holders, $11.8bn
Q2 20253 holders, $8.8m18 holders, $10.8bn
Q3 20254 holders, $76m16 holders, $13.8bn
Q4 20254 holders, $35m16 holders, $14.8bn
Q1 20264 holders, $38m11 holders, $12.3bn
Q2 20263 holders, $37m14 holders, $15.0bn
PRME

Prime Medicine Inc

Holders
3
Reported value
$51m
Buyers
3
Sellers
0

Breadth +3 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
13
Reported value
$6.8bn
Buyers
6
Sellers
8

Breadth -2 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2024

Among the 15 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only PRME (2)

ARK Investment Management LLC, Farallon Capital Management LLC

Only ARGX (12)

Artisan Partners LP, Capital World Investors, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Marshall Wace LLP, MFS Investment Management, Point72 Asset Management LP, Soros Fund Management LLC, T. Rowe Price Associates Inc

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →